Publications

Journal articles produced by the DSU and it’s network, broken down into topics:

Appraisal-specific

E Poku, J Rathbone, R Wong, E Everson-Hock, M Essat, A Pandor, A Wailoo. The safety of intravitreal bevacizumab monotherpay in adult ophthalmic conditions: systematic review. 2014 BMJ Open 4:e005244 doi:10.1136/bmjopen-2014-005244

A Wailoo, N Bansback, J Chilcott. Comment on: Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance: reply Rheumatology 2008; Vol 47 (10): 1590

A Wailoo, N Bansback, J Chilcott. Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance Rheumatology 2008; Vol 47 (2): 119-120

A Wailoo, A Sutton, A Morgan. The risk of febrile neutropenia in patients with non-small cell lung cancer treated with Docetaxel: a systematic review and meta-analysis 2009 British Journal of Cancer Vol 100: 436-441

S Lloyd, S Bujkiewicz, A Wailoo, A Sutton, D Scott. The effectiveness of anti-TNF-a therapies when used sequentially in rheumatoid arthritis patients: a systematic review and meta-analysis. Rheumatology 2010; Vol 49 (12): 2313-2321.

Methods development

A. Scope, A. Bhadhuri and B. Pennington (2022)  "Systematic Review of Cost-Utility Analyses That Have Included Carer and Family Member Health-Related Quality of Life".  Value in Health.  DOI: https://doi.org/10.1016/j.jval.2022.02.008

Rowen D, Mukuria C, Powell PA, Wailoo A. "Exploring the issues of valuing child and adolescent health states using a mixed sample of adolescents and adults". PharmacoEconomics, Accepted: 24 January 2022, Online 16/03/2022.

Laura A Gray, Monica Hernandez Alava and Allan J Wailoo (2021) Mapping the EORTC QLQ-C30 to EQ-5D-3L in patients with breast cancer. BMC Cancer 21:1237 DOI: https://bmccancer.biomedcentral.com/articles/10.1186/s12885-021-08964-5

A review of the psychometric performance of selected child and adolescent preference-based measures used to generate utility values for children. Value in Health 2020; ISSN 1098-3015; DOI: https://doi.org/10.1016/j.jval.2020.09.012

J Hill, D Rowen, R Pennington, A Wailoo, R Wong (2020) A review of the methods used to generate utility values in NICE technology assessments for children and adolescents. Value in Health, 2020, 23(7): 907-917. DOI: https://doi.org/10.1016/j.jval.2020.02.011

EQ5DMAP: A command for mapping between 3-level and 5-level EQ-5D (August 2018). To install the command within Stata use "ssc install eq5dmap".

The Impact of Moving from EQ-5D-3L to -5L in NICE Technology Appraisals (August 2018)

EQ-5D-5L versus EQ-5D-3L: The Impact on Cost-Effectiveness in the United Kingdom (October 2017)

S E Grimm, M Strong, A Brennan et al. (January 2016) Framework for analysing risk in Health Technology Assessments and its application to Managed Entry Agreements (PDF, 1.5MB)

S E Grimm, M Strong, A Brennan et al. (2017) The HTA Risk Analysis Chart: Visualising the Need for and Potential Value of Managed Entry Agreements in Health Technology Assessment. PharmacoEconomics 35: 1287

M Hernández Alava, A Wailoo. ALDVMM: A command for fitting Adjusted Limited Dependent Variable Mixture Models to EQ-5D. The Stata Journal 2015 In press. Available online.

B Pennington, S Davis (December 2014) Mapping from the Health Assessment Questionnaire to the EQ-5D: The Impact of Different Algorithms on Cost-Effectiveness Results. Value in Health 17(8):762-771

KK Shah, A Tsuchiya, A Wailoo (2015) Valuing health at the end of life: a stated preference discrete choice experiment. Social Science and Medicine; 124:48-56 (first published online November 2014)

M Hernández Alava, A Wailoo, F Wolfe, K Michaud (2014) A comparison of direct and indirect methods for the estimation of health utilities from clinical outcomes. Medical Decision Making; 34:919-930 (first published online 2013 doi: 10.1177/0272989X13500720)

O Ciani, S Davis, P Tappenden, R Garside, K Stein, A Cantrell, E D Saad, M Buse, R S Taylor (2014) Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers International Journal of Technology Assessment in Health Care; 30 (3): 312-324

KK Shah, A Tsuchiya, A Wailoo (2014) Valuing health at the end of life: an empirical study of public preferences. European Journal of Health Economics; 15 (4):389-399 (first published online May 2013; DOI: 10.1007/s10198-013-0482-3)

B Kearns, R Ara, A Wailoo, A Manca, M Hernandez Alava, K Abrams, M Campbell (2013) Good practice guidelines for the use of statistical regression models in economic evaluations. PharmacoEconomics; 31 (8): 643-652

P Thokala, A Duenas (2012) The applicability of Multi Criteria Decision Analysis for Health Technology Assessment. Value in Health; 15(8): 1172-1181

S Davis, A Wailoo (2013) A review of the psychometric performance of the EQ-5D in people with urinary incontinence. Health and Quality of Life Outcomes; 11 (20)

KK Shah, A Tsuchiya, A Wailoo. Valuing health at the end of life: an exploratory preference elicitation study (PDF, 364KB). HEDS Discussion Paper 11/17

J Morden, P Lambert, N Latimer, K Abrams, A Wailoo (2011) Assessing methods for dealing with treatment switching in randomised clinical trials: A simulation study BMC Medical Research Methodology; Vol 11:4

A Wailoo, A Tsuchiya, C McCabe (2009) Weighting must wait: incorporating equity concerns into cost-effectiveness analysis may take longer than expected. PharmacoEconomics; Vol 27 (12): 983-989

A Wailoo, A Sutton, N Cooper, D Turner, K Abrams, A Brennan, K Nicholson (2008) Cost-effectiveness and value of information analyses of neuraminidase inhibitors for the treatment of influenza. Value in Health; Vol 11 (2): 160-171.

Technical Support Documents

Population adjustment

D Phillipo, A Ades, S Dias, S Palmer, K Abrams, N Welton (February 2018) Methods for population-adjusted indirect comparisons in health technology appraisals. Med Decis Making; 38(2): 200-211. doi: 10.1177/0272989X17725740.

Evidence synthesis

S Dias, N Welton, A Sutton, A Ades (July 2013) Evidence Synthesis for Decision Making 1: Introduction Med Decis Making; 33: 597-606, doi: 10.1177/0272989X13487604

S Dias, A Sutton, A Ades, N Welton (July 2013) Evidence Synthesis for Decision Making 2: A Generalized Linear Modeling Framework for Pairwise and Network Meta-analysis of Randomized Controlled Trials Med Decis Making; 33: 607-617, first published on October 26, 2012, doi: 10.1177/0272989X12458724

S Dias, A Sutton, N Welton, A Ades (July 2013) Evidence Synthesis for Decision Making 3: Heterogeneity-Subgroups, Meta-Regression, Bias, and Bias-Adjustment Med Decis Making; 33: 618-640, doi: 10.1177/0272989X13485157

S Dias, N Welton, A Sutton, D Caldwell, G Lu, A Ades (July 2013) Evidence Synthesis for Decision Making 4: Inconsistency in Networks of Evidence Based on Randomized Controlled Trials Med Decis Making; 33:641-656, doi: 10.1177/0272989X12455847

S Dias, N Welton, A Sutton, A Ades (July 2013) Evidence Synthesis for Decision Making 5: The Baseline Natural History Model Med Decis Making; 33:657-670, doi: 10.1177/0272989X13485155

S Dias, A Sutton, N Welton, A Ades (July 2013) Evidence Synthesis for Decision Making 6: Embedding Evidence Synthesis in Probabilistic Cost-effectiveness Analysis Med Decis Making; 33: 671-678, doi: 10.1177/0272989X13487257

A Ades, D Caldwell, S Reken, N Welton, A Sutton, S Dias (July 2013) Evidence Synthesis for Decision Making 7: A Reviewer’s Checklist Med Decis Making; 33:679-691, doi: 10.1177/0272989X13485156

Utilities

Papaioannou, J Brazier, S Paisley (2013) Systematic searching and selection of health state utility values from the literature. Value in Health; 16 (4): 686-695

L Longworth, D Rowen (2013) Mapping to obtain EQ-5D utility values for use in NICE Health Technology Appraisals. Value in Health; 16 (1): 202-210

R Ara, A Wailoo (2012) Using Health State Utility Values in Models Exploring the Cost-Effectiveness of Health Technologies. Value in Health; 15: 6.

Survival analysis

N Latimer (2013) Survival analysis for economic evaluations alongside clinical trials – extrapolation with patient-level data. Inconsistencies, limitations, and a practical guide. Medical Decision Making; 33 (6): 743-754

A Bagust, S Beale (2013). Survival analysis and extrapolation modeling of time-to-event clinical trail data for economic evaluation: an alternative approach. Medical Decision Making; doi: 10.1177/0272989X13497998

N Latimer (2013). Response to “Survival analysis and extrapolation modeling of time-to-event clinical trial data for economic evaluation: an alternative approach” by Bagust and Beal. Medical Decision Making; doi: 10.1177/0272989X13511302

Methods Guide update process 2008

A Miners (2008) Estimating ‘costs’ for cost-effectiveness analysis. PharmacoEconomics Vol:26(9):745-751

A Sutton, A E Ades, N Cooper, K Abrams, (2008) Use of indirect and mixed treatment comparisons for technology assessment. PharmacoEconomics Vol:26 (9): 753-767

M Sculpher (2008) Subgroups and heterogeneity in cost-effectiveness analysis. PharmacoEconomics Vol: 26 (9): 799-806

C McCabe, K Claxton, A J Culyer (2008) The NICE cost-effectiveness threshold. What it is and what that means. PharmacoEconomics Vol: 26 (9): 733-744

K Claxton (2008) Exploring uncertainty in cost-effectiveness analysis. PharmacoEconomics Vol: 26: 781-798

J Brazier (2008) Valuing health states for use in cost-effectiveness analysis. PharmacoEconomics Vol: 26 (9): 769-779